Evidence map›Paper›PMID 35422103›Full record

ArticleThe Journal of antibiotics2022

Evaluation of a novel inhibitor of aspartate semialdehyde dehydrogenase as a potent antitubercular agent against Mycobacterium tuberculosis.

Ruifang Yang, Wenli Cao, Shengsheng Liu, Qiao Li, Yong Sun, Chen Liang, Weicong Ren, Yi Liu, Jianzhou Meng, Chuanyou Li

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ruifang YangDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Wenli CaoDepartment of Respiratory and Critical Care Medicine, Beijing Geriatric Hospital, Beijing, 100095, China.
Shengsheng LiuDepartment of Tuberculosis, Anhui Chest Hospital, Hefei, Anhui, 230022, China.
Qiao LiDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Yong SunDepartment of Clinical Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Chen LiangDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Weicong RenDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Yi LiuDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Jianzhou MengInstitute of Medical Biotechnology, Chinese Academy of Medical Sciences, Beijing, 100050, China. mengjianzhou@126.com.
Chuanyou LiDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China. lichuanyou@ccmu.edu.cn.
Capital Medical University · CNBeijing Chest Hospital · CNBeijing Geriatric Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNXi'an Chest Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81803412
6 · The paper itself

Abstract

The in vitro activity of IMB-XMA0038, a novel inhibitor targeting Mycobacterial tuberculosis (Mtb) aspartate semialdehyde dehydrogenase, was evaluated. Minimum inhibitory concentrations (MICs) of IMB-XMA0038 were against 20 Mtb isolates, including H37Rv (ATCC 27294), ten clinical pan-sensitive isolates, and nine clinical multidrug-resistant (MDR) isolates. In addition, minimum bactericidal concentrations (MBCs) were also determined against the H37Rv and 6 MDR isolates (the background information is same as above in order). A model was generated to evaluate IMB-XMA0038 activity against dormant Mtb. The post-antibiotic effect (PAE), an important indicator of antimicrobial drug dosing schedules to obtain efficacy, was determined based on time required for regrowth of Mtb to 50% of the OD

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsAspartate-Semialdehyde DehydrogenaseHumansMicrobial Sensitivity TestsRifampinAntitubercular AgentsAspartate-Semialdehyde DehydrogenaseRifampin

Identifiers

PMID35422103
OpenAlexW4224035501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.